Methods of treating wounds using cathepsin K inhibitors
AssigneeUniversity of Wyoming
InventorSreejayan Nair
Life of this patent
Estimating the term…
Abstract
Diabetic wounds have elevated levels of cathepsin K, a protease enzyme, which degrades proteins, such as collagen, causing delayed wound healing. By targeting cathepsin K, diabetic wound healing is ameliorated. Methods and devices for treatment include intradermal injection of odanacatib at or adjacent a wound. Methods and devices for treatment include topical application of pharmacological inhibitors of cathepsin K, for example, in the form of gel, powder, or bandage. Other methods and systems include localized genetic knock out of the cathepsin K gene by topical application of a small interfering RNA (siRNA) or antisense oligonucleotide to aid in wound healing.
Claims34
A method for treating a skin wound comprising:
- administering to the skin wound a therapeutic composition comprising an agent that degrades or inhibits cathepsin K;
- wherein the agent comprises at least one of odanacatib, cathepsin K inhibitor II, or an siRNA that has a sequence that is complementary to a nucleic acid sequence encoding cathepsin K;
- and,
- wherein the agent is intradermally administered in dosages ranging from 0.3 ng to 3000 ng per mm2 wound.
A topical formulation for treating a cutaneous wound comprising:
- a therapeutic composition comprising becaplermin and at least one of:
- odanacatib, cathepsin K inhibitor II, or an siRNA that has a sequence that is complementary to a nucleic acid sequence encoding cathepsin K;
- and
- a carrier, wherein:
- the carrier is provided as one of:
- a gel, an ointment, a paste, a lotion, a cream, a liquid, a spray, a foam, or a powder,
- the topical formulation is a mixture, suspension, solution, or emulsion, of the therapeutic composition with the carrier, and
- the topical formulation is configured to be applied to a skin surface without using physical penetration.
A method for treating a skin wound comprising:
- administering to the skin wound a therapeutic composition comprising an agent that degrades or inhibits cathepsin K;
- wherein the agent comprises at least one of:
- odanacatib, cathepsin K inhibitor II, or an siRNA that has a sequence that is complementary to a nucleic acid sequence encoding cathepsin K;
- and,
- wherein the agent is administered in a time-dependent regime, with an initial small dose, a subsequent large dose, and one or more following small doses, wherein the large dose provides the agent in a range of 1.5 to 100 times greater than provided in the small dose.
A method for treating a skin wound comprising:
- administering to the skin wound a therapeutic composition comprising an agent that degrades or inhibits cathepsin K;
- wherein the agent comprises at least one of odanacatib, cathepsin K inhibitor II, or an siRNA that has a sequence that is complementary to a nucleic acid sequence encoding cathepsin K;
- and,
- wherein the agent is intradermally administered at prescribed intervals of 2 to 7 days after initial wounding.
A method for treating a skin wound in a diabetic subject, comprising:
- topically administering to the skin wound a topical formulation comprising:
- an agent that degrades or inhibits cathepsin K, wherein the agent comprises odanacatib;
- and
- a carrier provided as one of:
- a gel, an ointment, a paste, a lotion, a cream, a liquid, a spray, a foam, or a powder;
- wherein:
- the topical formulation is a mixture, suspension, solution, or emulsion, of the agent with the carrier.
Dependencies are inferred from the claim text.